MIA
AZN icon

MeadowBrook Investment Advisors’s AstraZeneca AZN Stock Holding History

MeadowBrook Investment Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16
Closed -$2.42K – 338
2024
Q2 		$2.42K Hold
16
– – ﹤0.01% 291
2024
Q1 		$2.1K Hold
16
– – ﹤0.01% 300
2023
Q4 		$2.09K Buy
+16
New +$2.08K ﹤0.01% 311

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MeadowBrook Investment Advisors's AZN Position: Q3 2024 in Review

MeadowBrook Investment Advisors sold out of AstraZeneca (AZN) in Q3 2024, closing a stake of 16 shares — an estimated $2.42K sold.

MeadowBrook Investment Advisors first reported a position in AZN in Q4 2023 and held it in 3 quarters. The position peaked at $2.42K in Q2 2024. 1,230 funds tracked by Wall St. Rank hold AZN as of Q3 2024.

  • MeadowBrook Investment Advisors reported no remaining AstraZeneca position as of Q3 2024 after selling out during the quarter.
  • MeadowBrook Investment Advisors sold 16 AstraZeneca shares in Q3 2024, an estimated $2.42K.
  • MeadowBrook Investment Advisors first reported a position in AstraZeneca in Q4 2023 and held it in 3 quarters.
  • MeadowBrook Investment Advisors's AstraZeneca position peaked at $2.42K in Q2 2024.
  • 1,230 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.

Based on MeadowBrook Investment Advisors's 13F filing for Q3 2024, filed 6 Nov 2024.